Biogen (BIIB) Spikes 14% After FDA Posts Briefing Documents for Alzheimer's Drug Aducanumab
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/23/2026
- Wall St set to open lower as oil, bond yields tick up
- BTIG’s Krinsky warns 2000-like signals are mounting
- HSBC remains max bullish on stocks, tells investors to lean into tech
- Analyst explains why the midterm outcome is a “fundamental non-event”
- Oil holds near two-week lows while diesel cracks hit record
FDA Giving Biogen (BIIB) Option for Aducanumab Approval on Efficacy from ENGAGE Trial, Shares Worth $443 on Approval - Truist
November 4, 2020 10:54 AM ESTTruist Securities analyst Robyn Karnauskas weighed in on the FDA briefing documents for Biogen's (NASDAQ: BIIB) aducanumab, saying the FDA is giving BIIB the option for approval based on efficacy data from one trial (ENGAGE).
The analyst commented, "While we continue to review the FDA... More
Biogen (BIIB) Halted on LUDP
November 4, 2020 10:12 AM ESTBiogen (NASDAQ: BIIB) Halted on LUDP
... More